Clinical Trial Results:
Estudio multicéntrico, randomizado, doble ciego, con doble enmascaramiento, controlado frente a un comparador activo para evaluar la eficacia, seguridad y tolerancia de taspoglutida (RO5073031) comparado con pioglitazona en pacientes con diabetes mellitus tipo 2 controlados inadecuadamente con sulfonilurea (SU) en monoterapia o con la combinación metformina más sulfonilurea.
A multicenter, randomized, double blind (double dummy), active-comparator controlled study to compare the efficacy, safety and tolerability of taspoglutide versus pioglitazone in type 2 diabetes patients inadequately controlled with sulfonylurea (SU) monotherapy or metformin plus sulfonylurea combination therapy.
Summary
|
|
EudraCT number |
2009-009157-24 |
Trial protocol |
ES GB DE PL SK IT FR |
Global completion date |
30 Nov 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
20 Jul 2016
|
First version publication date |
20 Jul 2016
|
Other versions |
|
Summary report(s) |
BC21893_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.